MANKIND PHARMA
|
MANKIND PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 32.00 | 35.78 | 31.59 | 25.72 | 14.44 |
| CEPS(Rs) | 40.83 | 40.43 | 35.25 | 28.84 | 16.96 |
| DPS(Rs) | - | - | - | 3.10 | 4.45 |
| Book NAV/Share(Rs) | 185.61 | 153.65 | 117.88 | 87.00 | 70.47 |
| Tax Rate(%) | 21.63 | 26.42 | 23.56 | 26.54 | 30.20 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.89 | 24.66 | 25.50 | 23.68 | 18.57 |
| EBIT Margin(%) | 18.86 | 25.21 | 26.49 | 23.95 | 18.45 |
| Pre Tax Margin(%) | 18.35 | 24.47 | 26.16 | 23.57 | 17.56 |
| PAT Margin (%) | 14.38 | 18.00 | 20.00 | 17.31 | 12.26 |
| Cash Profit Margin (%) | 17.96 | 20.07 | 21.84 | 18.94 | 13.64 |
| Performance Ratios | |||||
| ROA(%) | 13.94 | 18.83 | 22.79 | 23.19 | 14.46 |
| ROE(%) | 19.27 | 26.72 | 31.51 | 33.48 | 21.41 |
| ROCE(%) | 23.49 | 33.96 | 39.97 | 43.57 | 28.80 |
| Asset Turnover(x) | 0.97 | 1.05 | 1.14 | 1.34 | 1.18 |
| Sales/Fixed Asset(x) | 1.92 | 2.52 | 3.12 | 3.33 | 3.42 |
| Working Capital/Sales(x) | 3.70 | 4.53 | 2.56 | 3.89 | 5.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.52 | 0.40 | 0.32 | 0.30 | 0.29 |
| Receivable days | 19.33 | 16.25 | 24.32 | 22.48 | 18.94 |
| Inventory Days | 65.31 | 66.57 | 58.78 | 51.46 | 59.01 |
| Payable days | 130.57 | 131.38 | 144.73 | 127.01 | 128.40 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | - | - | - | - | - |
| Price/Book(x) | - | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | -0.03 | 0.06 | -0.07 | -0.04 | 0.03 |
| EV/Core EBITDA(x) | -0.12 | 0.23 | -0.23 | -0.16 | 0.17 |
| EV/EBIT(x) | -0.15 | 0.25 | -0.25 | -0.17 | 0.18 |
| EV/CE(x) | -0.03 | 0.06 | -0.07 | -0.05 | 0.04 |
| M Cap / Sales | - | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.44 | 25.22 | 5.83 | 17.91 | 1.20 |
| Core EBITDA Growth(%) | -7.14 | 20.14 | 17.54 | 58.34 | -8.24 |
| EBIT Growth(%) | -15.60 | 18.78 | 17.23 | 59.00 | -9.91 |
| PAT Growth(%) | -9.86 | 12.37 | 22.43 | 73.00 | -9.13 |
| EPS Growth(%) | -10.58 | 13.28 | 22.81 | 78.11 | -11.88 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.14 | 0.05 | 0.04 | 0.10 |
| Current Ratio(x) | 2.32 | 1.68 | 2.87 | 2.25 | 1.90 |
| Quick Ratio(x) | 1.52 | 1.01 | 2.05 | 1.54 | 1.10 |
| Interest Cover(x) | 37.52 | 34.02 | 80.96 | 62.87 | 20.77 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹83,809.5 Cr | -6.5% | -7.6% | 57% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹368,598.0 Cr | 2% | -0.3% | 59.8% | Stock Analytics | |
| CIPLA | ₹114,654.0 Cr | 6% | 2.8% | 50.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹104,348.0 Cr | 3.7% | 5.8% | 17.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹101,499.0 Cr | 2.6% | 7.9% | 94.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,429.4 Cr | -1.3% | -2.8% | 31.5% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -6.5% |
-7.6% |
57% |
| SENSEX | 1.7% |
-0.8% |
19% |
You may also like the below Video Courses
